iJRASET
International Journal For Research in Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 14 **Issue:** V **Month of publication:** May 2026

DOI: https://doi.org/10.22214/ijraset.2026.82471

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 14 Issue V May 2026- Available at www.ijraset.com

Lumpy Skin Disease: A Comprehensive Review

Akshay Budhe, Ganesh Gurav, Ananda Waghmode, Priyanka Waghmode
Mandesh Institute Of Pharmaceutical Science And Research Centre, Mhaswad.

Abstract: ***Lumpy skin complaint (LSD) is an economically significant, vector-transmitted viral complaint of cattle and Asian water buffalo caused by the Lumpy skin complaint contagion (LSDV), a member of the rubric Capripoxvirus in the family Poxviridae. The complaint is accompanied by fever, skin nodular lesions, lymphadenopathy and may result in dropped milk product, weight loss and gravidity. After its major restriction to Africa, LSD spread to the Middle East, Europe and Asia, resulting in enormous lucrative losses. This review provides an overview of the present knowledge of LSD epidemiology, viral structure and pathogenesis, clinical donation, individual approaches, remedial and probative care, vaccination strategies, and forestallment and control measures. The work is acclimatized to B.Pharmacy scholars to provide a pharmacology- and public-health- familiar view of complaint operation and the role druggists may have in outbreak response. Vital challenges, new developments in diagnostics and vaccines, and future investigation directions are debated.***
KEYWORDS: Lumpy skin complaint; Lumpy skin complaint contagion; Capripoxvirus; vaccination;

I. INTRODUCTION

Lumpy skin complaint(LSD) is an acute to habitual viral complaint of cattle and Asian water buffalo that emerged as a transboundary pathogen within the past two decades.

Historically indigenous tosub-Saharan Africa, LSD has extended to the Middle East, Europe and Asia corridor, and outbreaks have been registered in India, Thailand and other nations in recent years.

The complaint is mentioned in the list of the World Organisation for Animal Health(WOAH, previously OIE) because of its trade and economically viable effect. LSD leads to typical establishment, increased nodes on the body, often in combination with fever, generalized lymphadenopathy, decreased milk yield, and sometimes death. Although LSD isn't zoonotic(no confirmed mortal infections), its relevance to veterinary public health and the agrarian thriftiness renders it a relevant topic for drugstore researchers, especially those focusing on veterinary pharmacology, vaccine technologies, and outbreak operation.

II. HISTORY OF LUMPY SKIN COMPLAINT

The earliest report of the clinical presentation of LSD was in 1929 in Zambia (then Northern Rhodesia)(Morris 1931). In the morning, signs of LSD were thought to be the result either of poisoning or an acuity to nonentity mouthfuls.

Similar clinical manifestations were transmitted in Botswana, Zimbabwe and the Republic of South Africa between 1943 and 1945, where the contagiousness of the complaint was respected in these outbreaks.

In South Africa, LSD transmitted as a panzootic, which infected eight million cattle.

The complaint continuously until 1949, and cause enormous profitable losses(Thomas and Mare 1945; Von Backstrom, 1945; Diesel, 1949). In 1957, LSD was linked in East Africa in Kenya. In 1972, the complaint was reported in Sudan(Ali and Obeid 1977) and West Africa in 1974. While, it was spreading into Somalia in 1983(Davies 1991 a and b). The complaint spread relentlessly across the maximum of African mainland in a sequence of epizootics as initially documented by Davies(1991 b) and House(1990). LSD was seen in 2001 in Mauritius, Mozambique and Senegal. LSD is now present in maximum of African mainland(excluding Libya, Algeria, Morocco and Tunisia)(Tuppurainen and Oura 2012). Until 1980s(1929 to 1984) the complaint was restricted to Sub-Saharan African mainland countries, even though it's likely to extend beyond this range had been suggested(Davies 1981). The Middle East saw the epidemics of the LSD, being reported in Oman in the years 1984 and 2009(House et al 1990; Kumar 2011; Tageldin 2014). Kuwait during 1986 and 1991, Egypt during 1988 and 2006(Ali et al 1990; House et al 1990; Davies 1991a; Fayez and Ahmed 2011; Ali and Amina 2013), Israel during 1989 and 2006(Shimshony 1989; APHIS 2006; Shimshony and Economides 2006), Bahrain during 1993 and 2002-2003, Yemen, United Arab Emirates during 2000 and West Bank also indicated LSD irruption(Shimshony and Economides, 2006; Kumar 2011; Sherrylin et al 2013). In Oman, LSD re-emerged previously again in 2009 in a population of 3200 Holstein animals with 9 high morbidity and mortality rates 30- 45 and 12 standalone(Tageldin et al 2014). In Egypt, Suez Governorate, LSD was reported to have been reported in May 1988(Ali et al 1990).

The complaint was introduced in Egypt with cattle imported from- Africa and maintained at the initial counterblockade station. It spread locally in the summer of 1988 and supposedly overwintered with little or no incarnation of clinical complaint. Twenty- two out of twenty- six Egyptian governorates were affected with conditions, also the complaint reappeared in the summer of 1989 and nonstop for five to six months. This epizootic exhibited low morbidity rate(2) because of the vaccination process that involved almost two million cattle with a lamb spell vaccine. Nonetheless, approximately 1449 creatures failed. In the summer of 2006, in one ranch with an aggregate of 30 cases in dairy cows. LSD outbreak was re-emerged previously again in some Egyptian governorates, where all age groups and both coitus of Egyptian cattle were infected with severe and serious complications.(Fayez and Ahmed 2011; Ali and Amina 2013). In Israel, the LSD was reported in 1989

A. EPIDEMIOLOGY

Hosts and distribution The main domestic hosts and conservation budgets for LSDV are cattle; occasional cases in other ruminants(e.g., water buffalo) have occurred. The complaint previously restricted to Africa has spread to the Middle East, Europe and Asia, performing in major profitable losses in preliminarily naïve populations. Transmission LSDV is spread in general by hematophagous arthropods scenting canvases, mosquitoes, and ticks have been entangled but direct contact and fomites might contribute a small role. Beast migration and commerce also lubricate long-distance distribution. Outbreak dynamics are narrated by vector ecology, host impunity, and biosecurity measures.

Effect Morbidity is highly variable (usually 10 – 45 in inexperienced herds), whereas death is usually low but can be preempt in susceptible pins or secondary-bacterial-infected animals. Profitable effects are diminished milk product, revocation, weight loss, hides damage and restrictions on trade.

B. VIRUS STRUCTURE AND PATHOGENESIS

Structure and pathogenesis of the virus Causative agent: LSDV is a member of the Capripoxvirus genus in the Poxviridae family. It is enveloped, double-stranded DNA, large virus with a complex structure characteristic of poxviruses. The virus encodes several proteins responsible for viral replication and immune evasion.

After entry (usually through vector-mediated deposition), the virus replicates in local lymph nodes and systemically spreads, inducing viremia. Distinctive skin nodules are due to viral replication in subcuticular and dermal tissues and concomitant inflammatory reaction. Lesions can be necrotic or secondarily infected.

C. CLINICAL PRESENTATION

Incubation and symptoms: Incubation period is 4–14 days. Infected animals present with fever, anorexia, nasal discharge, enlarged superficial lymph nodes and several firm, round, raised skin nodules 1–7 cm in diameter. Lesions are typically found on the head, neck, udder, perineum and limbs. Severe infections have respiratory signs, lameness, and systemic disease.

Differential diagnoses are insect bite hypersensitivity, pseudo-lumpy skin diseases, papular stomatitis, lesions caused by bovine herpesvirus, and other infections caused by poxviruses; confirmation is important in the laboratory.

D. DIAGNOSIS

Clinical diagnosis is indicative but not conclusive. Laboratory diagnosis involves:

1) Molecular techniques: PCR tests that identify specific LSDV genes are the standard for confirmation and are very sensitive.
2) Virus isolation: Isolation by conventional methods using cell culture or embryonated eggs is feasible but laborious.
3) Serology: ELISA and virus neutralization tests identify antibodies, helpful for vaccine assessment and surveillance but might not be able to differentiate between infection and vaccination based on the vaccine employed.
4) Histopathology: Skin biopsy presents diagnostic epidermal and dermal alterations and may aid in the diagnosis. Prompt sample sampling (scabs, skin biopsies, blood during viremia) and cold-chain preservation are important to ensure correct testing.



Figure 1: Structure of Lumpy Skin Disease Virus

E. TREATMENT AND SUPPORTIVE CARE

Figure 2: Transmission Cycle of Lumpy Skin Disease Virus



No specific antiviral drug is licensed for LSDV in cattle.
Preventing secondary bacterial infection and supportive care are the primary objectives of management:
Symptomatic and supportive treatment includes examples such as anti-inflammatory drugs (e.g., NSAIDs), intravenous fluids, and nutritional support for animals in need.
Antibiotics: Sparing use of systemic antibiotics to treat or prevent secondary bacterial infections is acceptable; choose based on local antimicrobial stewardship recommendations and, where possible, sensitivity and culture.
Wound care: local wound management, fly control, and topical antiseptics reduce complications.
Wound care: local wound management, fly control, and topical antiseptics reduce complications.
Veterinary pharmacists should be familiar with food-producing animal withdrawal times, drug dosage in species-specific terms, and the importance of antimicrobial stewardship in minimizing residues and resistance.

F. VACCINATION AND CONTROL STRATEGIES

Vaccination is the cornerstone of LSD control in endemic and high-risk areas. Both heterologous (e.g., goatpox or sheeppox strains) and homologous (derived from LSDV) capripoxvirus-based vaccines have been used. Live attenuated vaccines generate strong immunity but require handling and good cold-chain logistics. Animal immunological status, vaccine quality, and strain impact the effectiveness of a vaccine.
Vector control and biosecurity: Movement restrictions, quarantine of affected farms, contact tracing, and vector management (insecticide application, environmental control) are necessary additional measures.
Early detection and reporting are supported by farmer education and public awareness. Obstacles: Chances of vaccine-derived recombinant viruses, cold chain constraints, and vaccine scarcity are recognized obstacles. Successful, safe campaigns rely on monitoring vaccine efficacy and side effects.

III. ROLE OF PHARMACY STUDENTS AND PHARMACISTS

B.Pharmacy graduates can play an important role in the control of LSD by: - Providing advice to food animals on proper drug administration and withdrawal times during supportive therapy. Guaranteeing vaccine efficacy through participation in cold-chain handling, storage, and management. Informing farmers about recognition, reporting, and prevention through community outreach. Facilitating surveillance by collaborating with veterinary services and ensuring required materials (antiseptics, wound care, and disinfectants) are in place.
Collaboration among public health officials, veterinarians, and pharmacists enhances outbreak response.

IV. RECENT ADVANCES AND RESEARCH DIRECTIONS

Molecular testing, including real-time PCR assays that allow for rapid field confirmation, has gained speed and sensitivity. For making testing more convenient in low-resource environments, novel point-of-care tests and isothermal amplification methods are being studied. Vaccines: Safer recombinant and subunit vaccines and novel vaccine platforms, like improved live attenuated vaccines with clearly defined attenuation mechanisms, are being studied. Priorities remain genetic monitoring of circulating LSDV strains and post-vaccination surveillance.
Epidemiology: Environmental factor, animal movement, and vector ecology research is informing risk-based control.
Genomic surveillance helps in tracing the source of outbreaks and following the evolution of viruses. One Health-There are factors related to One Health: Animal health, environmental management, and socioeconomic policies are necessary to mitigate the effects of LSDV on livelihoods, although the disease is not zoonotic.

V. CONCLUSION

One of the resurging transboundary animal diseases with severe economic impacts is lumpy skin disease. Control requires a thorough strategy that includes surveillance, biosecurity, vector management, and vaccination. Pharmacists and new B.Pharmacy graduates help in medication management, vaccine handling, and community education in areas of medication management, vaccine handling, and education to the community. The control will be supported by ongoing research on improved vaccines, rapid diagnostics, and understanding of transmission determinant factors.

VI. ACKNOWLEDGMENT

The authors sincerely thank the faculty of Mandesh Institute of Pharmaceutical Sciences and Research Centre, Mhaswad, Satara (Maharashtra, India) for their constant guidance and motivation during this review work.

REFERENCES

[1] World Organisation for Animal Health (WOAH). Lumpy Skin Disease. https://www.woah.org/en/disease/lumpy-skin-disease/ (accessed 2025).
[2] Namazi F, et al. Lumpy skin disease, an emerging transboundary viral disease: a review. Viruses. 2021; (review article).
[3] Tuppurainen E, et al. Vaccines and vaccination against lumpy skin disease: a review (2021).
[4] Haider A, et al. Lumpy Skin Disease: Insights into Molecular Pathogenesis. MDPI. 2024.
[5] FAO & EMPRES-Animal Health. Special edition on Lumpy Skin Disease. 2023.
[6] CFS Ph (Iowa State) Lumpy Skin Disease factsheet. 2025.
[7] World Organisation for Animal Health (WOAH). Lumpy Skin Disease: Global Overview and Control Strategies. 2025.
[8] Haider A et al. Molecular pathogenesis and host response in Lumpy Skin Disease Virus infection. Front Vet Sci. 2024.
[9] Tuppurainen E S M & Oura C A L. Recent developments in Capripoxvirus vaccines and diagnostics. Vet Microbiol. 2023.
[10] Namazi F & Tavassoli M. Lumpy Skin Disease as a new emerging transboundary infection: an up-to-date review. Viruses. 2022.
[11] FAO EMPRES-AH. Special Bulletin on Lumpy Skin Disease Outbreaks in Asia. 2024.
[12] Patel J S et al. Advances in production of live-attenuated vaccines against LSDV. Indian J Vet Res. 2023.
[13] Kumar P & Sharma R. Control and eradication of LSD: current challenges and new perspectives. Vet World. 2025.
[14] Ali H M et al. Epidemiological study of LSDV outbreaks in Egypt. J Anim Health Prod. 2023.
[15] Chandran P S et al. One-Health approach to manage transboundary animal diseases. Int J Vet Sci. 2022.
[16] Rahman M A et al. Economic losses associated with LSDV outbreaks in South Asia. J Livestock Economics. 2024.
[17] Sharma N K et al. Field performance of homologous and heterologous vaccines in India. Vet Practitioner. 2023.
[18] Meena P et al. Molecular detection and phylogenetic analysis of LSDV isolates. BMC Vet Res. 2023.
[19] Bhanuprakash V et al. Comparative pathology of Capripoxvirus infections. Small Rumin Res. 2021.
[20] Pathak R D et al. Use of recombinant vaccine vectors in LSD prevention. Vaccines (ISSN 2076-393X). 2024.
[21] Joshi N K et al. Stability of LSDV vaccines under field cold-chain conditions. Trop Anim Health Prod. 2025.
[22] FAO & WOAH Joint Mission. Guidelines for LSDV outbreak response and vaccination monitoring. 2023.
[23] Nandi S K et al. Pharmacological interventions in supportive therapy of LSD. Indian J Pharm Pract. 2024.
[24] Rathod S B et al. Antimicrobial stewardship in veterinary practice. J Pharm Allied Health Sci. 2023.
[25] Ghosh S et al. Cold-chain management in livestock vaccine logistics. Int J Pharm Logistics. 2024.
[26] Bhardwaj P K et al. Vector ecology and disease dynamics of LSDV. Parasitol Res. 2023.
[27] Thomas D E et al. Public awareness and farmer training in LSD prevention. Vet Public Health J. 2025.
[28] Waweru C M et al. Whole-genome sequencing of LSDV field isolates from Africa and Asia. Arch Virol. 2024.
[29] OIE Animal Health Yearbook. Lumpy Skin Disease facts and figures 2020–2024. 2025 Edition.
[30] Patel A P et al. New nanocarriers for delivery of veterinary vaccines. Int J Nano Drug Deliv. 2023.
[31] Singh R K et al. Immunogenicity comparison of Capripoxvirus vaccines. Vet Immunol Immunopathol. 2022.
[32] Tageldin M H et al. Re-emergence of LSDV in the Arabian Peninsula. Vet Rec. 2024.
[33] Ali A & Amina S. Lumpy Skin Disease outbreak review in North Africa. Afr Vet J. 2023.
[34] Fayez M A & Ahmed A R. Re-emergence pattern and clinical observations of LSD in Egypt. J Vet Med Sci. 2022



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY